Abeona Therapeutics

ABEO · NASDAQ

$4.60+$0.19 (+4.31%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $4.41

ABEO analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 10 analysts

Average $19.25 (+318.5% upside)

Low: $14.14
Now: $4.60
High: $31.50

Upgrades and downgrades

The latest rating actions, newest first

ABEO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Cantor Fitzgerald	Sep 18, 2026	Maintains	Overweight	$28.00 → $30.00	41%
Roth Capital	Sep 17, 2026	Initiates	Buy	$17.00	44%
Oppenheimer	Aug 14, 2026	Maintains	Outperform	$22.00 → $21.00	33%
HC Wainwright & Co.	May 28, 2026	Maintains	Buy	$20.00	43%
HC Wainwright & Co.	Mar 19, 2026	Maintains	Buy	$20.00	43%
HC Wainwright & Co.	Mar 10, 2026	Maintains	Buy	$20.00	43%

The case for and against

Updated Oct 18, 2026

Bull case

Abeona Therapeutics is viewed favorably because ZEVASKYN has already shown strong efficacy, durability, and safety, with clinical data demonstrating reduced cerebrospinal fluid and plasma heparan sulfate alongside cognitive and behavioral gains, while its approved status supports near-term commercial execution in RDEB. The company’s operating momentum is reinforced by 1Q26 top-line revenue of $8.7M, six activated QTC sites, coverage policies for 95% of commercially insured U.S. lives, and a manufacturing footprint that can support up to six slots per month now, with additional capacity planned. Long-term upside also comes from a target U.S. patient pool of about 750, estimated 2026 revenue of $52.1M and 2027 revenue of $97.4M, and a path to cash flow-positive status around 2027 as scaling improves.

Bear case

Abeona Therapeutics is facing a negative fundamental setup because gene therapy carries elevated safety, regulatory, and reimbursement risk, including off-target effects, immune responses, and payor resistance to very expensive treatments. Commercial execution also looks fragile: 2Q revenue of $11.4M came in below the $13.4M and $12.1M expectations, only four of five treated patients were recognized, and management cited low manufacturing yield, biopsy-quality issues, a failed identity test, and two cancellations that hurt production slots. Even with seven active QTCs and an 84-hour stability window, the company is still early in process learning and may need more financing if ZEVASKYN uptake, manufacturing consistency, or launch economics disappoint.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.